SCHEMBL704879

SCHEMBL704879

Clc1cccc(-c2nnn[nH]2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.54
GAA P10253 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MPI P34949 1/20 0.49
GFER P55789 1/20 0.49
NOTUM Q6P988 3/20 0.47
HRH1 P35367 1/20 0.44
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MGAM O43451 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
SCN2A Q99250 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4339179 0.87 ALOX5 (0.47) IDO1GAAKDM4EALDH1A1MPI
SCHEMBL12761250 0.86 GP6 (0.37) IDO1GAAKDM4EALDH1A1MPI
SCHEMBL4344106 0.82 FYN (0.43) IDO1NOTUMNPC1TP53TSHR
SCHEMBL2288755 0.81 KMO (0.49) IDO1GAAKDM4EALDH1A1MPI
SCHEMBL4341054 0.81 PIK3CA (0.44) IDO1GAAKDM4EALDH1A1MPI
SCHEMBL705727 0.80 ALDH1A1 (0.42) IDO1ALDH1A1GFERTSHRRAB9A
SCHEMBL2406795 0.80 MEN1 (0.46) IDO1KDM4EALDH1A1NPC1TP53
SCHEMBL4655029 0.79 GP6 (0.49) GAAKDM4EALDH1A1NPC1JAK2
SCHEMBL16174510 0.79 IDO1 (0.37) IDO1GAAALDH1A1NOTUMSMN1; SMN2
SCHEMBL16855883 0.78 MAPK13 (0.44) KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US claimed
EP-2726515-B1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NAT RECH SCIENT (FR) 2015-04-01 EP claimed
US-20140206825-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-07-24 US claimed
EP-2726515-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES Centre National De La Recherche Scientifique (FR) 2014-05-07 EP claimed
WO-2013001235-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-01-03 WO claimed
CN-114306604-A Use of farnesyl transferase inhibitors for the treatment of cancer 库拉肿瘤学公司 2022-04-12 CN disclosed
EP-3976190-A1 NEW ENDOPEROXIDE COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES THEREOF FOR CONTROL OF PERKINSIOSIS IN BIVALVES CCMAR - Centro de Ciências Do Mar Universidade Do Algarve (PT) 2022-04-06 EP disclosed
CN-114107497-A Use of farnesyl transferase inhibitors for the treatment of cancer 库拉肿瘤学公司 2022-03-01 CN disclosed
WO-2020240266-A1 NEW ENDOPEROXIDE COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES THEREOF FOR CONTROL OF PERKINSIOSIS IN BIVALVES CCMAR - CENTRO DE CIÊNCIAS DO MAR UNIVERSIDADE DO ALGARVE (PT) 2020-12-03 WO disclosed
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US disclosed
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US disclosed
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US disclosed
EP-0230270-B1 FUSED BENZAZEPINES SCHERING CORPORATION (US) 1990-08-01 EP disclosed
EP-0254737-B1 FUSED BENZAZEPINES SCHERING CORPORATION (US) 1990-07-25 EP disclosed
US-4925777-A Direct positives FUJI PHOTO FILM CO., LTD. (JP) 1990-05-15 US disclosed
EP-0254737-A1 FUSED BENZAZEPINES. SCHERING CORP (US) 1988-02-03 EP disclosed
EP-0230270-A2 Fused benzazepines SCHERING CORPORATION (US) 1987-07-29 EP disclosed
US-4647572-A Iodoallyl and iodopropargyl substituted tetrazoles and anti-microbial compositions thereof MEIJI SEIKA KAISHA, LTD. (JP) 1987-03-03 US disclosed
EP-0107859-A1 Tetrazole compounds, process for preparing the same and antibacterial and antifungal compositions containing the same as active ingredient MEIJI SEIKA KAISHA LTD. (JP) 1984-05-09 EP disclosed
EP-0028717-A1 6,7-Benzomorphan derivatives, processes for their production, pharmaceutical compositions containing said derivatives and their use as pharmaceuticals ACF CHEMIEFARMA NV (NL) 1981-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206825-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES ALK, TST, TEKT1 IDO1 950/4885GAA 3403/4885KDM4E 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.